Substâncias enantiomericamente puras (SEP): a questão dos fármacos quirais

Detalhes bibliográficos
Autor(a) principal: Barreiro,Eliezer J.
Data de Publicação: 1997
Outros Autores: Ferreira,Vitor. F., Costa,Paulo R. R.
Tipo de documento: Artigo
Idioma: por
Título da fonte: Química Nova (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40421997000600014
Resumo: The thalidomide disaster, in the 60,s, is the most painful reminder of the importance of chirality for biological activity. After this episode, much attention has been devoted to study the correlations between toxicological and pharmacological properties and chirality. Actualy, to get a licence for a new chiral drug in EUA, European community and Japan, it is necessary to study the biological properties of each enatiomer independently. This article presents an overview about the importance of the chirality of organic compounds and its relationships with biological activity, asymmetric synthetic methodologies and market.
id SBQ-3_45bb742c5d6d3a5279d2acf7643313ef
oai_identifier_str oai:scielo:S0100-40421997000600014
network_acronym_str SBQ-3
network_name_str Química Nova (Online)
repository_id_str
spelling Substâncias enantiomericamente puras (SEP): a questão dos fármacos quiraischiral technologyasymmetric synthesisdrugs chiralityThe thalidomide disaster, in the 60,s, is the most painful reminder of the importance of chirality for biological activity. After this episode, much attention has been devoted to study the correlations between toxicological and pharmacological properties and chirality. Actualy, to get a licence for a new chiral drug in EUA, European community and Japan, it is necessary to study the biological properties of each enatiomer independently. This article presents an overview about the importance of the chirality of organic compounds and its relationships with biological activity, asymmetric synthetic methodologies and market.Sociedade Brasileira de Química1997-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40421997000600014Química Nova v.20 n.6 1997reponame:Química Nova (Online)instname:Sociedade Brasileira de Química (SBQ)instacron:SBQ10.1590/S0100-40421997000600014info:eu-repo/semantics/openAccessBarreiro,Eliezer J.Ferreira,Vitor. F.Costa,Paulo R. R.por2008-09-01T00:00:00Zoai:scielo:S0100-40421997000600014Revistahttps://www.scielo.br/j/qn/ONGhttps://old.scielo.br/oai/scielo-oai.phpquimicanova@sbq.org.br1678-70640100-4042opendoar:2008-09-01T00:00Química Nova (Online) - Sociedade Brasileira de Química (SBQ)false
dc.title.none.fl_str_mv Substâncias enantiomericamente puras (SEP): a questão dos fármacos quirais
title Substâncias enantiomericamente puras (SEP): a questão dos fármacos quirais
spellingShingle Substâncias enantiomericamente puras (SEP): a questão dos fármacos quirais
Barreiro,Eliezer J.
chiral technology
asymmetric synthesis
drugs chirality
title_short Substâncias enantiomericamente puras (SEP): a questão dos fármacos quirais
title_full Substâncias enantiomericamente puras (SEP): a questão dos fármacos quirais
title_fullStr Substâncias enantiomericamente puras (SEP): a questão dos fármacos quirais
title_full_unstemmed Substâncias enantiomericamente puras (SEP): a questão dos fármacos quirais
title_sort Substâncias enantiomericamente puras (SEP): a questão dos fármacos quirais
author Barreiro,Eliezer J.
author_facet Barreiro,Eliezer J.
Ferreira,Vitor. F.
Costa,Paulo R. R.
author_role author
author2 Ferreira,Vitor. F.
Costa,Paulo R. R.
author2_role author
author
dc.contributor.author.fl_str_mv Barreiro,Eliezer J.
Ferreira,Vitor. F.
Costa,Paulo R. R.
dc.subject.por.fl_str_mv chiral technology
asymmetric synthesis
drugs chirality
topic chiral technology
asymmetric synthesis
drugs chirality
description The thalidomide disaster, in the 60,s, is the most painful reminder of the importance of chirality for biological activity. After this episode, much attention has been devoted to study the correlations between toxicological and pharmacological properties and chirality. Actualy, to get a licence for a new chiral drug in EUA, European community and Japan, it is necessary to study the biological properties of each enatiomer independently. This article presents an overview about the importance of the chirality of organic compounds and its relationships with biological activity, asymmetric synthetic methodologies and market.
publishDate 1997
dc.date.none.fl_str_mv 1997-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40421997000600014
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40421997000600014
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv 10.1590/S0100-40421997000600014
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Química
publisher.none.fl_str_mv Sociedade Brasileira de Química
dc.source.none.fl_str_mv Química Nova v.20 n.6 1997
reponame:Química Nova (Online)
instname:Sociedade Brasileira de Química (SBQ)
instacron:SBQ
instname_str Sociedade Brasileira de Química (SBQ)
instacron_str SBQ
institution SBQ
reponame_str Química Nova (Online)
collection Química Nova (Online)
repository.name.fl_str_mv Química Nova (Online) - Sociedade Brasileira de Química (SBQ)
repository.mail.fl_str_mv quimicanova@sbq.org.br
_version_ 1750318100158349312

Registros relacionados